Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Private Placements
SUBSCRIBE
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold Price
Silver Price
Copper Price
Oil Price
Uranium
Artificial Intelligence

Gilead Sciences

NASDAQ:GILD
CEO Interviews
Press Releases

Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation

Gilead Emphasizes Unique Ways To Hire Top Talent

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera

INNspired
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology.

*Disclaimer: This profile is sponsored by Gilead Sciences ( NASDAQ:GILD ). This profile provides information which was sourced by the Investing News Network (INN) and approved by Gilead Sciences in order to help investors learn more about the company. Gilead Sciences is a client of INN. The company's campaign fees pay for INN to create and update this profile.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Gilead Sciences and seek advice from a qualified investment advisor.

The Conversation (0)

Interactive Chart

×